The European Commission launched a EUR 16 million call for tenders to establish an investigational vaccine reserve for filoviruses such as Marburg, Sudan, Ebola and Bundibugyo viruses.
90% confidence
HealthEuropean Union
Omissions
The tender was formally published by the European Health and Digital Executive Agency (HaDEA) on behalf of HERA under the EU4Health programme; the MEP's 'we launched' phrasing is consistent with her role as a Commissioner, but the executing agency is HaDEA.
The call is a 'pilot' reserve and was published on 3 June 2026, matching the claim's 'last month' relative to the 8 July 2026 session date.
The full list of viruses (Marburg, Sudan, Ebola, Bundibugyo) is consistent with official descriptions (which explicitly cite Marburg MARV and the human-pathogenic filoviruses), though the official tender page snippet confirms Marburg explicitly; secondary sources confirm Marburg, Sudan and Ebola.
Sources
PrimaryHaDEA — European Health and Digital Executive Agency (European Commission)Call for tenders published 3 June 2026: 'Clinical trial preparedness for filovirus outbreaks through the establishment of a pilot vaccine reserve'. HaDEA has published the call for tenders HADEA/2026/OP/0019: Clinical Trial Readiness through the Establishment of a Pilot Filovirus Investigational Vaccine Reserve. 'Specifically, the call has the objective of establishing, piloting and maintaining a reserve of candidate vaccines targeting human-pathogenic [filoviruses]'.
PrimaryEU Funding & Tenders Portal (European Commission)Tender HADEA/2026/OP/0019-PIN: 'This call for tenders aims to ensure clinical trial preparedness for Filovirus outbreaks through the establishment of an EU-based reserve of investigational [vaccines]. Specifically, the call aims to establish, pilot and maintain an investigational reserve of Filovirus candidate vaccines against Marburg (MARV) ...'. DevelopmentAid lists 'Estimated total value: 16000000 EUR' for this procedure.
Secondarybio-m (Biomedical Alliance media/news)'HERA plans two EU4Health tenders for May 2026: Next-generation therapeutics for infectious diseases and Filovirus investigational vaccine reserve (Marburg, Sudan, Ebola)'.
SecondaryLovguiden.dk (public procurement news)'HaDEA has published tender HADEA/2026/OP/0019 with a budget framework of €16 million and an application deadline of 24 August 2026' (EU launches €16m tender for filovirus vaccine reserve).
SecondaryNCP Brussels (National Contact Point, funding opportunities)'This call for tenders aims to ensure clinical trial preparedness for Filovirus outbreaks through the establishment of an EU-based reserve of investigational [vaccines]. Total budget: EUR 16 million, with an expected 1 tenderer to be awarded. Project duration: 48 months.'
SecondaryHealth Research Board Ireland — EU funding updates'HADEA/2026/OP/0019 ... Filovirus Investigational Vaccine Reserve. Publication date 3 June 2026; deadline 02 September 2026; indicative budget €16 million.'